The Pacific Treatment & Research in Psychedelics (TRIP) Program is dedicated to the development of psychedelic-assisted therapies and the scientific exploration of how altered states of consciousness can be harnessed to change behavior and improve brain health and quality of life. We serve all California communities.

Why TRIP?

Behavioral health issues are a leading cause of disability and they remain inadequately treated worldwide.

The modest effectiveness of existing treatments such as antidepressants and traditional psychotherapy approaches show us that there is an urgent need for more effective treatments for conditions such as depression, alcoholism, smoking cessation, and end of life suffering.

Early studies of psychedelic-assisted therapies for these conditions have demonstrated much larger and durable effects compared to existing therapies suggesting that there is great potential for psychedelic-assisted treatments to revolutionize the treatment of mental health and behavioral disorders.

About Dr. Heinzerling

Dr. Keith Heinzerling practices internal medicine and is an addiction medicine specialist at the Pacific Brain Health Center. His clinical and research focuses are on the treatment of alcohol, drug and substance use problems, with anti-addiction medications. As director of the TRIP program, he is involved in the development of psychedelic-assisted therapies for those suffering from addiction, depression, anxiety, and PTSD.

Dr. Heinzerling takes a hands-on, compassionate approach. He works with his patients during the preparatory phase of psychedelic-assisted therapy to alleviate any concerns. As a trained guide, he has a deep clinical understanding of the psychedelic journey and the importance of integrating insights. He follows each patient through their treatment path so that they gain the most benefit from this medical treatment modality.

Dr. Heinzerling believes that psychedelic-assisted therapies will provide healing benefits for multiple conditions in the future including in the grief and oncology settings. His goal is for PNI is to become one of the leading U.S. centers for psychedelic-assisted therapy research, clinical trials and ultimately delivery of these eventual FDA-approved therapies.

Dr. Heinzerling understands the qualities of well-being and aims for his patients to understand their relationship with themselves, bonds with others, and connectedness to nature.